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 Periodontitis begins as a microbial infection, followed by host-mediated destruction 
of soft tissue caused by hyperactivated or primed leukocytes and the generation of 
cytokines, eicosanoids, and matrix metalloproteinases that cause significant connective 
tissue and bone destruction. Cytokines, such as Interleukin- 1β, Tumor Necrosis Factor-α, 
prostaglandin E2, and recently leptin, have been shown to orchestrate the host response to 
infectious and inflammatory stimuli.
1
 
In 1994, Jeffrey M. Friedman and Douglas L. Coleman discovered leptin through the 
study of  mice at the Rockefeller University.
2
Leptin, a peptide hormone is produced 
predominantly by white adipose cells, although low levels have been detected in the 
hypothalamus, pituitary,
3
 stomach,
4
 skeletal muscle
5
, mammary epithelia,
6
 chondrocytes, 
placenta,
7
gastric epithelium,
8
  T cells,
9
 gingiva,
10
 osteoblasts,
11
 and in intercalated, striated, 
and intralobular ducts as well as in basal parts of the acini  in the major salivary glands.
12
 
The mature protein, encoded by the obese (ob) gene is localized into human and 
mouse 7 and 6 chromosomes, respectively. Zhang et al., studied the effects of leptin through 
mutant obese mice from the mouse colony at the Jackson Laboratory.
13
It was found that 
mutations in the gene encoding  the protein hormone leptin "ob/ob" and receptor for leptin 
"db/db" were the possible cause for massively obese mice. When ob/ob mice were 
administered with recombinant leptin, decrease in food intake and body weight was 
observed.
2
 Thus leptin is regarded as a „ Fasting signal‟.  
Leptin which is structurally and functionally related to the Interlukin - 6 cytokine 
family is a 16 kDa non-glycosylated protein, characterized by a long chain four-helical 
bundle structure and a pair of conserved cysteine residues  to form a disulfide bridge 
required for full biological activity.
14
The leptin receptor Ob-R (or Lepr), is a member of the 
class I cytokine receptor family, which includes gp-130, the common signal transducing 
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receptor for the Interlukin-6 related family of cytokines. In humans, three expressions of Ob-
R gene have been reported. They are Ob-Ra, Ob-Rb and Ob-Rc mRNA. Among them, Ob-
Rb is abundantly expressed in the hypothalamus and controls the energy balance of the 
body.
15
  Leptin, the „fat sensor‟, not only monitors weight but also modulates glucose and 
lipid metabolism, thermo-genesis, neuro-endocrine function, reproduction, immunity, bone 
remodeling and cardiovascular function.
5
 
B and T lymphocytes also express leptin receptor Ob-Rb, thereby directly regulating 
the B and T cell responses.
16
 It activates cytokine-like signal transduction via the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway by binding to 
the long leptin receptor isoform (LEPRb). In addition, AMP-activated protein kinase 
(AMPK) is another important intracellular enzyme in leptin transduction mechanisms.
2
 
Modulation of the immune system by leptin is exerted at the development, proliferation, 
antiapoptotic, maturation, and activation levels
17
 and is mediated by the regulation of 
hematopoiesis and lymphopoiesis. 
Moreover, leptin receptors have been found in neutrophils, monocytes, and 
lymphocytes which suggest that leptin has a proinflammatory effect in the immune system. 
Leptin enhances the progression of periodontitis by mediating the promotion of T-helper 1 
responses and production of other proinflammatory cytokines, such as Tumor Necrosis 
Factor-α, Interleukin-2, Interleukin-6.16 Hence, it is evident that leptin plays an influential 
role in the mechanisms of immune response and host defense. Therefore it can be 
ascertained that the expression of leptin is modulated in a similar manner to the cytokine 
response to infectious and inflammatory stimuli in periodontitis.  Despite the fact that poor 
periodontal health is linked to higher levels of several systemic markers, only few studies
(18–
20)
 have tried to elucidate whether successful periodontal treatment can reduce the levels of 
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these serological markers. In this conjecture, the present study evaluated serum and salivary 
leptin concentrations between healthy and patients with chronic periodontitis and to 
elucidate the effect of Non Surgical Periodontal Therapy (NSPT) on serum and salivary 
leptin concentrations in chronic periodontitis. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims & Objectives
Aim and objective 
4 
 
 
AIM 
i. To compare the salivary and serum  leptin concentrations between healthy 
individuals and  chronic periodontitis patients. 
ii. To evaluate the effect of non surgical periodontal therapy on  serum and salivary 
concentrations of leptin in patients with chronic periodontitis. 
OBJECTIVE 
 To measure the serum and salivary leptin levels in subjects with and without chronic 
periodontitis by ELISA. 
 To assess whether NSPT can alter the salivary and serum leptin levels in chronic 
periodontitis. 
 To correlate the salivary and serum leptin levels with clinical parameters before and 
after NSPT.  
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The Biology Of Leptin 
Theodore et al.,1997
21
 stated that leptin is derived from the Greek word  leptos, 
meaning "thin". It is the “hormone of energy expenditure”, predominantly produced 
by adipose cells that helps to regulate energy balance by inhibiting hunger. Leptin is 
opposed by the actions of the hormone ghrelin, the "hunger hormone". Both hormones act 
on receptors in the arcuate nucleus of the hypothalamus to regulate appetite to 
achieve energy homeostasis. They pioneered the concept that adipose tissue is not an inert 
energy storage organ but an active endocrine organ. 
Licinio et al.,2000
22
 found that leptin is secreted in a pulsatile fashion and has a 
significant diurnal variation with higher levels in the evening and early morning hours. 
Circulating leptin levels reflect primarily the amount of energy stored in fat and secondarily 
acute changes in caloric intake. Factors promoting leptin secretion are excess energy stored 
as fat (obesity), Overfeeding, Glucose, Insulin, Glucocorticoids, Estrogens, Inflammatory 
cytokines, including Tumor Necrosis Factor-α and Interleukin-6. Factors inhibiting leptin 
secretion arelow energy states with decreased fat stores,fasting, catecholamines and 
adrenergic agonists, thyroid hormones, androgens, peroxisome, Proliferator-activated 
Receptor-γ (PPARγ) agonists. 
Role Of Leptin In Energy Homeostasis 
Elmquist JK etal.,2006
23
 experimented rat brain and found thatleptin mediates its 
effects by binding to specific leptin receptors (ObRs) expressed in the brainas well as in 
peripheral tissues. Alternative splicing generates several isoforms of ObRs. TheObRa 
isoform (the short leptin receptor isoform) is thought to play an important role intransporting 
leptin across the blood–brain barrier. The ObRb isoform (the long leptinreceptor isoform) 
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mediates signal transduction and is strongly expressed in the hypothalamus,an important site 
for the regulation of energy homeostasis and neuroendocrine function.   
 
Robertson SA et al.,2008
24
 interpreted that the circulating leptin level serves as a 
gauge for energy reserves and directs the central nervoussystem to adjust food intake and 
energy expenditure accordingly. Leptin exerts immediateeffects by acting on the brain to 
regulate appetite via ObRb-receptor binding in thehypothalamus.Leptin activates a complex 
neural circuit comprising of anorexigenic (i.e.appetite-diminishing) and orexigenic (i.e. 
appetite-stimulating) neuropeptides to control foodintake. Outside of the hypothalamus, 
leptin interacts with the mesolimbic dopamine system and nucleus of the solitary tractof the 
brainstem to contribute to satiety.It not only signals the central nervous system to decrease 
food intake, but alsoincrease energy expenditure. 
Roth JD et al.,2009
25
 found that patients with congenital leptin deficiency due to 
mutations in the leptin gene orextreme leptin resistance due to mutations of the leptin 
receptor gene are obese due to marked hyperphagia. For patients with leptin deficiency, 
administering leptin in replacementdoses reduce food intake via neural circuits that diminish 
the perception of food reward andenhance the response to satiety signals and normalizes 
body weight. However, leptinadministration at pharmacologic doses to the vast majority of 
obese humans, who haverelatively high levels of leptin and are resistant to it, induces little if 
any weight loss.Thus, accumulating evidence suggests that leptin is physiologically more 
important as anindicator of energy deficiency and as a possible mediator of adaptation to 
starvation
.
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Leptin In Saliva 
De Matteis R et al.,2010
26
carried out a detailed study of human salivary glands as 
potential leptin-producing organs. Biopsiesof salivary glands (submandibular and parotid) 
obtained from male and female patients during surgery for differentclinical indications were 
subjected to immunohistochemical study for the presence of leptin, its functional 
receptor,insulin and glucagon. Double immunohistochemical staining (silver–gold 
intensification and avidin–biotin–peroxidase) wasused for the visualization of glucagon and 
leptin labelling, respectively. The results showed that intralobularduct cells of 
submandibular and parotid glands are immunoreactive for leptin, leptin receptor and 
glucagonbut not for insulin.  
Bohlender J et al.,2014
27
 found leptin distributed throughout themajor salivary 
glands with obvious intracellular concentrationsin granula. In contrast, immunostaining for 
theleptin receptor was found exclusively in the membranes ofthe glandular cells. A high 
density of the leptin receptorwas localised in the epithelia of the duct lumen. PCRanalysis 
proved the autonomous expression of leptin bythe salivary glands independently from 
adipocytes.In the light of recent findings ofleptin influencing the growth of rodent salivary 
glands, thepresence and distribution of leptin and its receptor suggestsan autocrine role of 
salivary leptin within the glands. 
Lucena S et al.,2016
28
assessed if the induction of increased levels of circulating 
leptin influence the immunohistochemical expression of leptin at the level of major salivary 
glands in Wistar rats. It was found that the expression, in qualitative terms of leptin has been 
positive, being more evident in submandibular and sublingual glands, either in the acini or 
ducts. The results suggest that circulating leptin levels may not affect the expression of this 
hormone in the major salivary glands. 
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Role Of Leptin In Immunity 
G.Matarese et al.,2000
17
  indicated that the primary amino acid sequence of leptin  
belong to the long-chain helical cytokine family, such as IL-2, IL-12, and IL-6. In fact, 
leptin receptor (Ob-R) shows sequence homology to members of class I cytokine receptor 
(gp130) superfamily that includes the receptor for IL-6, leucocyte inhibitory factor (LIF), 
and   granulocyte colony-stimulating factor (G-CSF). Moreover, Ob-R has been shown to 
have the signaling capabilities of IL-6-type cytokine receptors, activating JAK-STAT, PI3K,   
and MAPK signaling pathways. In this context, a role for leptin in the regulation of innate 
immunity has been proposed. Consistent with this role of leptin in the mechanisms of   
immune response and host defense, circulating leptin levels are increased upon infectious 
and inflammatory stimuli such as LPS, turpentine, and cytokines.  
C. Mart´ın-Romero et al.,200029 demonstrated that Human leptin alone is not able 
to  activate human peripheral blood lymphocytes in vitro even though leptin receptor is 
present and activated in T   lymphocytes.  However, when T lymphocytes are costimulated 
with  phytohaemagglutinin(PHA) or concanavalin A (Con A), leptin dose-dependently  
enhances the proliferation and activation of cultured T lymphocytes, achieving maximal 
effect at 10 nm concentration. However, when  maximal concentrations of PHA or Con A 
are employed,   leptin has no further effect. These effects of leptin on T lymphocytes are 
observed even in the absence of monocytes, suggesting a direct effect of human leptin on 
circulating T   lymphocytes when they are costimulated.  
F.Maingrette et al.,2003
30
 assesed leptin regulating monocyte function in vitro 
experiments measuring free radical production and found leptin was shown to stimulate the 
oxidative burst in  monocytes and binding of leptin at the macrophage cell surface increases 
lipoprotein lipase expression through oxidative stress and protein kinase-C (PKC) dependent 
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pathways. Leptin at 1 ng/ml, mediates the inflammatory infiltrate and induces tissue factor 
expression in   human peripheral blood mononuclear cells. On the other hand, human leptin 
seems to downregulate oxidative  burst in previously activated monocytes. 
C. K. Wong et al.,2007
31
  explained that leptin could upregulate cell surface  
expression of adhesion molecules ICAM-1 and CD18 on eosinophils but suppress ICAM-3 
and L-selectin. Moreover, leptin could also stimulate the chemokinesis of eosinophils and 
induce the release of inflammatory cytokines IL-1β and IL-6 and  chemokines IL-8, growth-
related oncogene-alpha, and monocyte chemoattractant protein-1.  
K. Claycombe et al.,2008
32
 found that Leptin  signaling deficiency impairs humoral 
and cellular immunity. The leptin receptor Ob-Rb is expressed by B and T lymphocytes, 
suggesting that leptin regulates directly the B   and T cell responses. The leptin modulation 
of the immune system is also mediated by the regulation of hematopoiesis and 
lymphopoiesis.  Thus, seven days of provision of recombinant  leptin promoted substantial 
lymphopoiesis, with a  twofold increase of the numbers of B cells in the marrow of obese 
mice while doubling and tripling, respectively, the numbers of pre-B and immature B cells. 
Twelve days of supplementation  brought these subpopulations to near-normal   proportions. 
Leptin treatment also facilitated myelopoiesis such that the marrow of the obese mice 
contained normal  numbers of monocytes and granulocytes after 7 days.  
N. Kiguchi et al.,2009
33
 conducted an in vitro study and found that  human leptin  
stimulating proliferation and  activation of human circulating monocytes, promoting   the 
expression of activation markers: CD69, CD25,   CD38, and CD71, in addition to increasing 
the expression of monocytes surface markers, such as HLA-DR, CD11b andCD11c. 
Besides, leptin potentiates the stimulatory effect of LPS  on the proliferation and activation 
of human monocytes. Moreover, leptin dose-dependently stimulates the production of  TNF-
Review Of Literature 
 
10 
 
α and IL-6 and enhances chemokine ligand expression in cultured murine macrophage, 
through  activation of a JAK2-STAT3 pathway.  
B. Mattioli et al.,2009
34
  stated  that  Leptin  induces functional and morphological   
changes in human dendritic cells, directing  them towards Th1 priming and promoting DC 
survival   via the phosphoinositide 3 kinase (PI3K) signaling pathway. The involvement  of 
leptin signaling in dendritic cell survival and maturation has been observed in leptin receptor 
(Ob-R) deficient db/db mice. db/db mice displayed markedly reduced expression of 
costimulatory molecules and a Th2-type cytokine profile, with poor capacity to stimulate 
allogenic T cell proliferation. Thus, leptin has also been found to decreases MIP-1-α 
production by dendritic cells. Similar to leptin effect on monocytes, it may increase the 
survival of dendritic cells, and it may also  increase the expression of surface molecules, 
such as CD1a,   CD80, CD83, or CD86.  
The Role Of Leptin In Systemic Diseases 
Karmazyn et al.,2008
35
 described some of the cardioprotectiveeffects of leptin which 
included reduced extent of myocardialinfarction (MI) and protection against 
reperfusiondamage by local autocrine effects (the heart itself alsoproduces leptin) probably 
mediated through nitric oxide and alsoantilipotoxic effects. 
Seufert J et al.,2010
36
 examined pancreatic islets isolated from pancreas of human 
donors for their responses to leptin. The presence of leptin receptors on islet β-cells was 
demonstrated by double fluorescence confocal microscopy. They suggested that 
desensitization of leptin reception at the levels of the hypothalamus and the pancreatic β-
cells resulted in hyperphagia and hyperinsulinemia, respectively which may be important 
factors in the pathogenesis of adipogenic diabetes mellitus.  
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Menha Swellam et al.,2012
37
 assessed the role of soluble leptinand LepRb in non 
alcoholic fatty liver disease (NAFLD) and investigated whether leptin receptorgene (LepR) 
single nucleotide polymorphism influences NAFLD complicated with or without type 2 
diabetes mellitus(T2DM). Blood samples from 90 obese NAFLD cases and 30lean controls 
of matched age and sex were recruited in the study.Among the NAFLD patients, 43 were 
T2DM. Mutant LepRgenotype were significantly higher in mild–severesteatosis and in 
NAFLD with type 2 diabetes mellitus when compared with mild steatosisand those without 
T2DM. Elevatedleptin level seems to be a feature of steatosis, and it appears toincrease as 
hepatocyte steatosis develops. Moreover, polymorphismof LepR gene contributes to the 
onset of NAFLD by regulating lipidmetabolism and affecting insulin sensitivity.
 
Manole et al.,2013
38
 leptin stated that leptin is involved in the inductionand progression 
of experimental autoimmune encephalomyelitis (EAE). The immunomodulatoryeffects of 
leptin have also been linked to enhanced susceptibility to other autoimmunedisease such as 
multiple sclerosis.They suggested that increased leptin secretion occurs in acute phases of 
multiple sclerosis and correlates with CSF production of IFN.
 
VanSaun et al.,2015
39
 found that tumor-associated leptin receptor levels contribute to 
tumor growth and progression. Increaseddetection of ObR in ovarian cancers was correlated 
withdecreased survival. Three single-nucleotide polymorphisms in the leptin receptorgene 
(K109R, K656N, and Q223R) showed an associationwith increased basal-like breast cancer 
risk. Theseresults suggest that tumor leptin receptor levels directlyinfluence growth and 
progression. 
Smekal et al.,2017
40
 found that chronic intravenous administration of leptin 
increasesheart rate and mean arterial blood pressure by activationof the sympathetic nervous 
system and increased releaseof catecholamines. Another mechanism described in the 
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development of hypertension in which leptinhas been found to decrease diuresis and 
increased sodiumreuptake in the kidneys. Elevated leptin levels are associatedwith 
myocardial infarction and stroke, independentlyof traditional risk factors or obesity and are 
associatedwith calcification of the coronary arteries. 
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A case control and quasi experimental study which involved patients visiting the 
Department of Periodontics in Vivekanandha Dental College for women was conducted. 
The study was approved by the Institutional ethics committee.  Before the commencement 
of the study, it was clearly explained and informed consent was obtained from all patients. 
A total of 60 participants with normal Body Mass Index (18.5-24.9 kg/m
2
)
41
were 
enrolled in the study.Patients with chronic periodontitis were diagnosed based on the 
American Academy of Periodontology Task Force Report on the Update to the 1999 
Classification of Periodontal Diseases and Conditions.
42
 They were divided into three 
groups based on the following criteria. 
INCLUSION CRITERIA 
GROUP A: Healthy Volunteers (n=26) 
 Systemically and periodontally healthy individuals 
 Good oral hygiene 
 Probing depth (PD) <3mm 
 No clinical attachment loss (CAL) 
 Plaque index44 [PI] <1 
 Gingival index45 [GI] <1 
Group B: Chronic Periodontitis before treatment (n=30)  
 Patients with signs of gingival inflammation  
 Presence of bleeding on probing 
 Clinical Attachment Loss > 4mm  
 PD>4mm  
 Radiographic evidence of bone loss 
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Group B1: Chronic Periodontitis after treatment (n=30) 
 Group B patients underwent  non surgical periodontal therapy and revaluated after 3 
months 
EXCLUSION CRITERIA: 
 Use of tobacco in any form 
 Alcoholism 
 Pregnancy 
 Presence of any gross pathology and systemic disease. 
 Any periodontal therapy in the past 12 months 
 Aggressive Periodontitis 
 Any antimicrobial, anti inflammatory therapy       
 Immunosuppressive therapy for the past 6 months 
Sociodemographic characteristics of the study population: 
 This included bio social and metabolic variables, frequency of tooth brushing and 
number of teeth present in the oral cavity. Biosocial variables comprise of age, gender  and 
socio-economic status (SES).  Metabolic variable included measurement of BMI. All the 
informations were obtained by questioning the participants verbally. All participants were in 
the age group of 31 to 65 years. There was almost equal distribution of males and females. 
Group A (healthy) comprised of 13 males and 13 females. Group B (Chronic Periodontitis) 
comprised of  16 males and 14 females. Socioeconomic status was assessed by Modified 
Prasad classification
43
 as follows: 
Class 1 - ≥  Rs 5156 
Class 2 -     Rs 2578 –5155  
Class 3 -     Rs 1547 –2577 
Materials and Methods 
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Class 4- Rs 773–1546 
 Class 5- ≤ Rs773 
BMI was calculated based on each subject‟s weight in kilograms divided by the 
square of his height in meters (kg/m
2
). Participants with normal weight classified based on 
WHO recommendations
41
 were included in the study. 
<16 kg/m
2
              -severe underweight  
16·0–16·9 kg/m2   -moderate underweight  
17·0–18·49 kg/m2 -mild underweight 
18·5–24·9 kg/m2   -normal range  
≥25 kg/m2             -overweight  
25–29·9 kg/m2      -preoboese 
 ≥30 kg/m2            -obesity  
30–39·9 kg/m2     - obese class I  
35–39·9 kg/m2     -obese class II 
≥40 kg/m2           - obese class III 
Clinical examination: 
A thorough medical, dental, personal history was obtained from each patient. All the 
clinical parameters were examined after collection of clinical samples in order to avoid 
contamination of the samples at baseline and at recall visits. For each patient,  Turesky et al 
1970 plaque index (PI),
44
 Loe and Silness 1975 gingival index (GI),
45
  Ainamo and Bay 
1975 Gingival Bleeding Index (GBI),
46
 probing depth (PD) and clinical attachment loss (CA 
loss) were recorded at baseline and after 3 months.  
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Turesky et al Plaque Index, 1970: 
 Disclosing agent was applied on both buccal and lingual surfaces  and patient was 
advised to rinse with water. Scores were recorded based on the following criteria. 
Scores Criteria 
0 No plaque 
1 Separate flecks of plaque at the cervical margin of the tooth 
2 A thin continuos band of plaque (up to one mm) at the cervical 
margin of the tooth 
3 A band of plaque wider than one mm but covering less than one-third 
of the crown of the tooth 
4 Plaque covering at least one-third but less than two-thirds of the 
crown of the tooth 
5 Plaque covering two-thirds or more of the crown of the tooth 
 
Loe and Silness Gingival Index, 1963 
The severity of gingivitis is scored on distal facial papilla, facial margin, mesial 
facial papilla, entire lingual margin of selected teeth. 
Score Criteria 
0 Normal gingiva. 
 
1 Mild inflammation- - slight change in color, slight edema. No bleeding on 
probing. 
 
2 Moderate inflammation -- redness, edema and glazing. Bleeding on probing. 
 
3 Severe inflammation -- marked redness and edema. Tendency to spontaneous 
bleeding. Ulceration. 
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Ainamo and Bay Gingival Bleeding Index,1975: 
 It is performed through gentle probing of the orifice of the gingival crevice by No 23 
explorer. If bleeding occurs within 10seconds, positive finding is recorded and then 
expressed as a percentage of the number of sites examined. 
Probing depth and Clinical Attachment Level: 
 Pressure sensitive probe calibrated in millimeters was used to examine  six 
sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual and distolingual) on each tooth 
excluding the third molars. Probing depth is measured from gingival margin to base of the 
pocket and Clinical attachment level is measured from cementoenamel junction to base of 
the pocket. 
Collection of clinical samples 
Clinical samples (saliva and blood) were collected at baseline and after 3 months.The 
patients were asked to abstain from eating and drinking (except for water) for two hours 
before collecting samples. They were made to sit comfortably in an upright position on the 
dental chair 
Collection of saliva 
The subjects were advised to rinse his or her mouth with  distilled water and then to 
relax for five minutes. Whole unstimulated saliva (4 ml) was collected by modified draining 
method as depicted in figure-1. They were asked to expectorate into disposable 
polypropylene tubes fitted with a funnel for ease of collection every 30 s over a period of 5 
min. Saliva samples were immediately centrifuged at 3000 rpm for 5 min to remove the cell 
debris and 2ml of the supernatant was pippetted out in 5 ml aliquots and stored at -80
0
C until 
analysis. 
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Collection of serum 
Four  milliliters  of blood was collected from the ante cubital fossa by venipuncture 
using 20 gauge needles with a 5 ml syringe as depicted in figure-2. Blood sample was 
allowed to clot at room temperature and after 1 hour, serum was extracted from blood by 
centrifuging at 3000rpm for 5 min and 2 ml of the extracted serum was transferred to 5ml 
aliquots and stored at -80
0
C (as shown in figure-4) till the time of assay. 
Non Surgical Periodontal Therapy 
Non-surgical periodontal treatment (NSPT) included scaling and root planing (SRP) 
and institution of oral hygiene instructions  which was performed with the help of ultrasonic 
scalers(Woodpecker) and hand curettes (Hu-Friedy curretes, Chicago, IL, U.S.A) for 
patients with chronic periodontitis . Scaling was done on the day of initial collection of 
samples and root planning was completed within 2 weeks after the enrollment of the 
participants in the study. All patients were instructed to perform modified Bass method of 
brushing twice in a day and dental flossing.They were refrained from mouthwashes, 
antimicrobials during the course of study. They were contacted via telephone once in 15 
days to ensure whether they follow oral hygiene instructions properly 
Analysis of leptin by ELISA: 
 The RayBio® Human Leptin ELISA kit, GA, USA was used to quantify the serum 
and salivary leptin concentrations. The following reagents and materials are used. 
Reagents used: 
Component  Size / Description 
Leptin Microplate  
(Item A) 
96 wells (12 strips x 8 wells) coated with anti-     
Human Leptin. 
Wash Buffer Concentrate     (20X) 
(Item B) 
25 ml of 20X concentrated solution. 
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Standard Protein  
(Item C) 
2 vials of Human Leptin. 1 vial is enough to run     
each standard in duplicate. 
Detection Antibody Leptin     
 (Item F) 
2 vials of biotinylated anti-Human Leptin. Each     
vial is enough to assay half the microplate. 
HRP-Streptavidin     Concentrate  
(Item G) 
200 μl 160X concentrated HRP-conjugated     
streptavidin. 
TMB One-Step Substrate     Reagent 
(Item H) 
12 ml of 3,3,5,5'-tetramethylbenzidine (TMB) in     
buffer solution. 
Stop Solution (Item I) 8 ml of 0.2 M sulfuric acid. 
Assay Diluent A (Item D) 30 ml of diluent buffer, 0.09% sodium azide as     
preservative. 
Assay Diluent B (Item E) 15 ml of 5X concentrated buffer. 
 
Additional materials  
1. Microplate reader capable of measuring absorbance at 450 nm. 
2. Precision pipettes to deliver 2 μl to 1 ml volumes. 
3. Adjustable 1-25 ml pipettes for reagent preparation. 
4. 100 ml and 1 liter graduated cylinders. 
5. Absorbent paper. 
6. Distilled or deionized water. 
7. Log-log graph paper or computer and software for ELISA data analysis. 
8. Tubes to prepare standard or sample dilutions. 
Reagent preparation 
1. All reagents and samples were brought to room temperature (18 - 25ºC) before use. 
2. Assay Diluent B (Item E)  was diluted 5-fold with deionized or distilled water before use. 
3. Sample dilution: Assay Diluent A (Item D) was used for dilution of serum samples. 1X 
Assay Diluent B (Item E) was used for dilution of cell culture supernatant samples.  
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4. Preparation of standard: 440 μl Assay Diluent A (for serum/ samples) or 1X Assay 
Diluent B (for salivary samples) was added into Item C vial to prepare a 220 ng/ml standard. 
The powder was dissolved thoroughly by a gentle mix. 2μl Leptin standard was added from 
the vial of Item C, into a tube with 1098 μl Assay Diluent A or 1XAssay Diluent B to 
prepare a 400 pg/ml stock standard solution. 300 μl Assay Diluent A or 1X Assay Diluent B 
was pipetted into each tube.  Stock standard solution was used to produce a dilution series as 
shown below. Each tube was mixed thoroughly before the next transfer. Assay Diluent A or 
1X Assay Diluent B served as the zero standard (0 pg/ml). 
   
Std 1 
 
Std 2 
 
Std 3 
 
Std 4 
 
Std 5 
 
Std 6 
 
Std 7 
Zero 
standard 
Diluent 
Volume 
Item 
C+  
440 µl 
1098 
µl 
300µl 300µl 300µl 300µl 300µl 300µl 300µl 
Conc. 220  
ng/ml 
400 
pg/ml 
160 
pg/ml 
64 
pg/ml 
25.6 
pg/ml 
10.24 
pg/ml 
4.1 
pg/ml 
1.64 
pg/ml 
0 pg/ml 
 
5. 20 ml of Wash Buffer Concentrate (20X) (Item B)  was diluted into  distilled water to 
yield 400 ml of 1X Wash Buffer. 
6. Detection Antibody vial (Item F) was spinned before use.  100 μl of 1X Assay was added 
to Diluent B (Item E) into the vial to prepare a detection antibody concentrate and pipetted 
up and down to mix gently. The detection antibody concentrate was diluted 80-fold with 1X 
Assay Diluent B (Item E).  
7. The HRP-Streptavidin concentrate vial (Item G) was spinned and pipetted up and down to 
mix gently before use, as precipitates may form during storage. HRP-Streptavidin 
concentrate was diluted 160-fold with 1X Assay Diluent B (Item E). 
Assay procedure     
1. 100 μl of each standard  and sample was added into appropriate wells. Wells were 
covered and incubated for 2.5 hours at 36
0
C  with  gentle shaking.     
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2. The solution was discarded and washed 4 times with 1X Wash Solution. Each well was 
filled with wash Buffer (300 μl) using a Pipette. After the last wash, remaining wash Buffer 
was aspirated. The plate was inverted and blotted  against clean paper towels.     
3. 100 μl of 1X prepared biotinylated antibody was added  to each  well and incubated for 1 
hour.    
4. The solution was discarded and washed as decribed above.     
5. 100 μl of prepared Streptavidin solution was added to each  well and incubated for 45 
minutes      
6. The solution was discarded and washed again  
7. 100 μl of TMB was added to One-Step Substrate Reagent (Item H) to each well and 
incubated for 30 minutes.  
8. 50 μl of Stop Solution (Item I) was added to each well and read at 450 nm immediately.     
Standard curve: 
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Sensitivity   
The minimum detectable dose of Human Leptin was determined to be 1 pg/ml.      
Specificity     
The Leptin ELISA kit shows no cross-reactivity with any of the cytokines tested: 
Human  Angiogenin, BDNF, BLC, ENA-78, FGF-4, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, 
IL-5, IL-7, IL- 8, IL-9, IL-10, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, I-309, IP-10, G-
CSF, GM-CSF, IFN gamma, MCP- 1, MCP-2, MCP-3, MDC, MIP-1 alpha, MIP-1 beta, 
MIP-1 delta, PARC, PDGF, RANTES, SCF, TARC, TGF-beta, TIMP-1, TIMP-2, TNF-
alpha, TNF-beta, TPO, VEGF. 
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APPENDIX - 1 
 
PROFORMA 
 
Dissertation title: Evaluation of salivary and serum leptin concentrations in healthy and 
chronic periodontitisindividuals before and after non surgical periodontal therapy. 
 
Name    :                                                                                     Date:     
 
Age/Sex:                                                                               O.P.No  : 
 
Address:                                                                                 Income : 
 
                                                    HISTORY 
 
Chief Complaint: 
 
Past Medical History: 
 
Past Dental History: 
 
Personal History: 
 
General Examination:  
Height : 
Weight: 
BMI     :  
Intra Oral Examination: 
No of teeth 
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INDICES 
BASELINE 
  
PLAQUE INDEX (Turesky et al 1970) : 
 
              
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
              
 
              
47 46 45 44 43 42 41 31 32 33 34 35 36 37 
              
 
 
 
Score: 
 
Interpretation : 
 
 
GINGIVAL INDEX (Loe&Silness 1963): 
 
      
16 12 24 36 32 44 
      
 
Score: 
 
Interpretation: 
 
 
GINGIVAL BLEEDING INDEX  (Ainamo &Bay 1975) 
 
              
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
              
 
              
47 46 45 44 43 42 41 31 32 33 34 35 36 37 
              
 
 
No of sites: 
 
Percentage of sites: 
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RADIOGRAPHIC FINDINGS: 
 
 
 
 
 
 
 
 
 
 
DIAGNOSIS: 
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INDICES 
3 MONTHS 
  
PLAQUE INDEX (Turesky et al 1970) : 
 
              
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
              
 
              
47 46 45 44 43 42 41 31 32 33 34 35 36 37 
              
 
 
Score: 
 
Interpretation : 
 
 
GINGIVAL INDEX (Loe&Silness 1963): 
 
      
16 12 24 36 32 44 
      
 
Score: 
 
Interpretation: 
 
 
GINGIVAL BLEEDING INDEX  (Ainamo &Bay 1975): 
 
              
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
              
 
              
47 46 45 44 43 42 41 31 32 33 34 35 36 37 
              
 
No of sites: 
 
Percentage of sites: 
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LEPTIN ANALYSES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
BASELINE                     AFTER 3 MONTHS 
Serum leptin level 
 
  
Salivary leptin level 
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INFORMED CONSENT FORM 
விவவகானந்தா பல் ஫ருத்துவகல்லூரி 
திருச்செங்வகாடு 
 
ஈறுந ோய் சிகிச்சச பிரிவு 
ஒப்புதல் படிவம் 
 
 
 
 
 
 
சப஬ர்        -     ஆண் / சபண் -          
முகவரி      -    வ஬து-          
 
 
 
 
……………………………………………………ஆகி஬ எனக்கு பரிவொதனன 
பற்மி஬ அனனத்து விவ஭ங்களும் சதரிவாக எடுத்துச஭க்கப்பட்டது. 
என் எல்யா ெந்வதகங்களுக்கும் பதில் அரிக்கப்பட்டன. என் எச்சில் 
஫ாதிரி ஫ற்றும் இ஭த்த஫ாதிரி எடுப்பதற்கும் பரிநசோதசனகளுக்கும் 
முழு஫னநதோடு ஒப்புக்சகாள்கிவமன்.   
 
 
 
சகய஬ோப்பம் 
நததி 
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APPENDIX – 2 
ARMAMENTARIUM 
MATERIALS AND INSTRUMENTS USED FOR CLINICAL STUDY 
 Gloves 
 Mouth mask 
 Patient apron 
 Chair apron 
 Head cap 
 Sterile cotton rolls 
 Gauze 
 Saline  
 Kidney tray  
 Betadine  
 Lignocaine  
 Syringe  
 Mouth mirror 
 Explorer  
 Tweezer  
 Pressure sensitive probe  
 Ultrasonic Scalers 
 Hu – Friedy Gracey Curettes 
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MATERIALS AND INSTRUMENTS USED FOR IMMUNOCHEMICAL ANALYSIS 
 Polypropylene tube 
 Borosil funnel 
 Tourniquet 
 5 ml syringe 
 Centrifuge 
 micropipette 
 5 ml aliquots 
 Deep freezer 
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ARMAMENTARIUM 
 
Instruments used for NSPT 
 
Figure -1   
 
Contents of human leptin ELISA kit 
 
Figure-2 
Photographs 
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Measurement of PD and CAL using Pressure Sensitive Probe 
 
Figure -3 
 
Preoperative View 
 
Figure - 4 
Postoperative View 
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Figure – 5 
 
COLLECTION AND STORAGE OF SAMPLES 
 
 
Collection of saliva                                                            Collection of blood 
                  
                   Figure – 6                                                              Figure - 7 
 
  
 
Centrifugation of saliva and serum                    Storage of  samplesat  -80
0 
C deep freezer 
                
                      Figure – 8                                                                 Figure - 9 
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ANALYSIS OF LEPTIN BY ELISA 
 
 
 
Stored saliva and serum samples                          Samples showing positive for leptin 
 
     
                    Figure – 10                                                                Figure – 11 
 
 
 
 
 
Incubator used for leptin analysis                   ELISA reader used to assess the leptin levels 
                   
                     Figure – 12                                                                   Figure - 13
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Statistical analysis: 
 Statistical analysis was carried out using Statistical Package for Social Sciences 
(SPSS) version 20.0. Continuous variables were represented as mean and standard deviation 
(SD)  and categorical variables were represented as frequency and percentage.The data was 
found to benormally distributed. Chi square test was used to assess sociodemographic 
characteristics of the study population. Intergroup comparision (between healthy and chronic 
periodontitis) was carried out through independent t test. Intragroup comparision (before and 
after NSPT) was analysed through paired t test.  
Sample size calculation 
 The software used to calculate the sample size is GPower version 3.1.9.2. It was 
determined that 13 patients per group would be necessary to provide a 95% power with an 
alpha error of 0.05.However, based on an anticipated attrition rate of 25%, 30 patients per 
group were included in this study. 
Sociodemographic characteristics: 
 In terms of age, gender, socioeconomic status, number of teeth, frequency of 
brushing and BMI, there was no statistically significant difference (P>0.05) determined 
through chi square test  between group A (healthy individuals) and group B (chronic 
periodontitis) as depicted in table 1. 
Clinical parameters: 
 Independent t test was used to compare the clinical parameters between healthy and 
chronic periodontitis. Table 2 shows patients with chronic periodontitis (group B) exhibited 
significantly higher scores of PI, GI, GBI, PD, CAL, % of sites with BOP, PD>4mm, 
CAL>5mm than healthy individuals (group A). 
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Comparision of Salivary and serum leptin levels between healthy and Chronic 
Periodontitis : 
 All salivary and serum samples tested positive for the leptin assay except for two 
salivary samples in group B. Independent t test was used for comparison of clinical samples. 
The mean serum leptin levels were significantly higher in patients with chronic periodontitis 
(288.263±64.7439 pg/ml) than healthy individuals (26.412±8.6102 pg/ml). On the contrary, 
mean salivary leptin levels were significantly higher in healthy individuals (10.450± 3.9180 
pg/ml) than patients with chronic periodontitis (3.153± .2058 pg/ml) as depicted in table 3. 
 Comparision of periodontal parameters in patients with chronic periodontitis before 
and after NSPT by paired t test: 
 All the clinical parameters, reevaluated after 3 months of NSPT showed reduction in 
periodontitis patients.  The analysis of variance showed that the differences in PI,GI, GBI, 
PD, CAL, % of sites with BOP, PD>4mm, CAL>4mm were found to be statistically 
significant (p < 0.05) , as depicted in table 4. 
Comparison of the biochemical parameters in patients with chronic periodontitis  
before and after NSPT by paired t test: 
 Patients with chronic periodontitis underwent NSPT and  salivary, serum leptin 
levels were revaluated after 3 months. Salivary leptin levels were significantly elevated from 
baseline (3.153± .2058 pg/ml) to (10.897± 3.6653 pg/ml)whereas serum leptin levels were 
significantly decreased from baseline (288.263±64.7439 pg/ml) to (77.330± 7.1509 pg/ml)  
as depicted in table 5. 
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Pearson’s correlation among serum, salivary leptin levels and PD, CAL: 
 There was a significant positive correlation (p<0.001) among serum leptin 
concentrations, PD (+0.956, +0.933, +0.874) and CAL (+0.989, +0.958, +0.976)  in group 
A, group B and group B1 but a negative significant correlation was found among salivary 
leptin concentration, PD (-0.960, -0.942, -0.782)  and CAL (-0.846, -0.965, -0.978)  in group 
A, group B and group C, which is shown in table 6,7,8. 
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TABLE 1: SOCIODEMOGRAPHIC CHARACTERISTICS OF THE STUDY 
POPULATION 
CHARACTERISTIC GROUP A 
N=26 
GROUP B 
N=30 
P VALUE 
AGE 46.77±9.061 44.87±8.705 >0.05 
MALES 13 (50%) 16 (53.3%) >0.05 
FEMALES 13(50%) 14(46.7%) >0.05 
SOCIO ECONOMIC STATUS 
CLASS I 
CLASS II 
CLASS III 
CLASS IV 
CLASS V 
 
13 (50.0%) 
7   (42.3%) 
4   (15.3%) 
1   (3.8%) 
1   (3.8%) 
 
10  (33.3%) 
8    (50.0%) 
7    (23.3%) 
 2   (6.7%) 
3    (10.0%) 
 
 
>0.05 
NUMBER OF TEETH 29.08±2.667 29.13±2.515 >0.05 
FREQUENCY OF TOOTH 
BRUSHING 
ONCE DAILY 
TWICE DAILY 
 
21 (80.8%) 
5 (19.2%) 
 
27 (90.0%) 
3 (10%) 
 
>0.05 
BMI 22.750±1.8435 22.657±1.8658 >0.05 
 
TABLE 2:COMPARISION OF CLINICAL PARAMETERS BETWEEN HEALTHY 
AND CHRONIC PERIODONTITIS 
CLINICAL 
PARAMETERS 
GROUP A 
N=26 
GROUP B 
N=30 
MEAN 
DIFFERENCE 
P VALUE 
PLAQUE INDEX 0.388 ±.2227 2.993±.5938 -2.605 < 0.05 
GINGIVAL INDEX 0.00 2.06±1.79 -2.06 < 0.05 
BOP (%) 0.00 99.8 -99.80 < 0.05 
PD (mm) 2.273±0.5127 5.270±0.8703 -2.997 < 0.05 
CAL (mm) 1.0388±0.4879 6.1000±0.8870 -5.061 < 0.05 
PD>4mm(%) 0.00 49.43±10.052 -49.43 < 0.05 
CAL>5mm(%) 0.00 48.01±13.457 -48.01 < 0.05 
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TABLE 3: COMPARISION OF BIOCHEMICAL PARAMETERS BETWEEN 
HEALTHY AND CHRONIC PERIODONTITIS 
BIOCHEMICAL 
PARAMETERS 
GROUP A GROUP B MEAN 
DIFFERENCE 
P VALUE 
SERUM 
LEPTIN 
26.412±8.6102 288.263±64.7439 
 
-261.852 
< 0.05 
SALIVARY 
LEPTIN 
 
10.450± 3.9180 
 
3.153± .2058 
7.297 < 0.05 
 
 
TABLE 4: COMPARISION OF CLINICAL PARAMETERS BEFORE AND AFTER 
NSPT 
CLINICAL PARAMETERS GROUP B 
N=30 
GROUP B1 
N=30 
T P VALUE 
PLAQUE INDEX 2.993±.5938 1.63± .396 10.476 < 0.05 
GINGIVAL INDEX 2.06±1.79 1.111± .2030 23.164 < 0.05 
BOP (%) 99.8 19.80± 
13.428 
32.554 < 0.05 
PD (mm) 5.270±0.8703 2.393± .6736 27.480 < 0.05 
CAL (mm) 6.1000±0.8870 3.093± .6938 38.600 < 0.05 
PD>4mm(%) 
49.43±10.052 
29.93± 
10.359 
31.869 
< 0.05 
CAL>5mm(%) 48.01±13.457 29.63± 7.449 13.809 < 0.05 
 
 
TABLE 5: COMPARISION OF BIOCHEMICAL PARAMETERS BEFORE AND 
AFTER NSPT 
BIOCHEMICAL 
PARAMETERS 
GROUP B GROUP B1 T P VALUE 
SERUM 
LEPTIN 
288.263±64.7439 77.330± 7.1509 
17.747 < 0.05 
SALIVARY 
LEPTIN 
3.153± .2058 10.897± 3.6653 -10.959 < 0.05 
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TABLE 6: PEARSON’S CORRELATION FOR GROUP A 
   PD (mm) CAL (mm) 
Serum leptin 
(pg/ml) 
r 
0.956(**) 0.989(**) 
  P <0.001 <0.001 
Salivary leptin 
(pg/ml) 
r 
-0.960(**) -0.846(**) 
  P <0.001 <0.001 
 
 
TABLE 7: PEARSON’S CORRELATION FOR GROUP B 
   PD (mm) CAL (mm) 
Serum leptin 
(pg/ml) 
r 
0.933(**) 0.958(**) 
  P <0.001 <0.001 
Salivary leptin 
(pg/ml) 
r 
-0.942(**) -0.965(**) 
  P <0.001 <0.001 
 
 
TABLE 8: PEARSON’S CORRELATION FOR GROUP B1 
   PD (mm) CAL (mm) 
Serum leptin 
(pg/ml) 
r 
0.874(**) 0.976(**) 
  P <0.001 <0.001 
Salivary leptin 
(pg/ml) 
r 
-0.782(**) -0.978(**) 
  P <0.001 <0.001 
 
** - highly significant 
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Graph – 1: Comparision of Plaque Index among healthy,CP before & after NSPT 
 
 
 
 
Graph - 2: Comparision Of Gingival Index In CP Patients before and after NSPT 
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Graph - 3: Comparision Of sites with bleeding on probing in CP Patients 
 before and after NSPT 
 
 
 
 
Graph - 4: Comparision Of Probing Depth among healthy and in CP Patients 
 before and after NSPT 
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Graph - 5: Comparision Of Clinical Attachment Level among healthy and in CP Patients 
 before and after NSPT 
 
 
 
Graph -6: Comparision Of serum leptin levels among healthy and in CP Patients 
 before and after NSPT 
 
 
 
Graphs 
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Graph -7: Comparision Of salivary leptin levels among healthy and in CP Patients 
 before and after NSPT 
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Chronic periodontitis which is the second most widespread dental disease
47
 is 
initiated by microbes but progressed by cytokines and other host related factors. The 
principal finding of the study concentrated on alteration in salivary and serum leptin 
levelson the grounds that leptin which is a regulator of energy homeostasis,can be 
considered a link between theneuroendocrine and immune systembecause of its dual nature 
as a hormoneand a cytokine. It is a part ofthe cytokine network that governs 
theinflammatory/immune response and hostdefensemechanisms.  
This study included participants with normal BMI which is considered as an 
important criteria because leptin levels are altered in obese individuals, as detected by the 
following study. Zimmermann in 2013
48
 evaluated the local and circulating levels of leptin 
in obese and  normal weight individuals with and without CP. Individuals with normal 
weight, non periodontitis group showed lowest levels of serum leptin. Among the obese 
group, patients without periodontitis reported leptin concentrations of 479.6 – 253.6 whereas 
patients with chronic periodontitis showed leptin concentrations of 426.8 – 280.9. Their 
study implied the dominating role of obesity  in the circulating levels of leptin than 
periodontitis. For this reason, all healthy individuals and chronic periodontitis patients who 
have a normal BMI were included in this study. 
Obesity not only affects the concentrations of leptin but also it perturbs the action of 
leptin. Ducy et al. conducted a study in obese mice to assess the role of leptin in bone 
remodeling.  Leptin expression could not be detected in whole bone samples even after a 
long exposure, providing an indirect argument against a paracrine regulation of osteoblast 
function by leptin. The lack of leptin expression in osteoblasts rules out an autocrine 
mechanism. Osteoblast cultured from mice underwent long term leptin treatment on 
extracellular matrix synthesis and bone matrix mineralization but observed no difference in 
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collagen synthesis or formation of mineralization nodules between control and leptin-treated 
cultures. In contrast, administration of small doses of leptin in the third ventricle of mice, 
leads to bone remodeling.This latter result signified that osteoblastic function is affected by 
leptin binding to its hypothalamic receptor and unveils the central nature of bone remodeling 
regulation. They related their study to humans and conveyed that obese individuals, in 
whom the serum leptin levels are highly resistant to  the biologic effects of leptin. It is 
because of this resistance, transportation of leptin to the central nervous system is impaired 
in obese individuals.
49
 
Apart from obesity, smokers, pregnant females and  aggressive periodontitis were 
excluded from the study as a result of the following proven studies. Bozkurt et al 
50
 in 2006 
evaluated influence of  smoking on GCF leptin concentrations  in patients with chronic 
periodontitis. They reported that  GCF  leptin levels  were significantly lower in smokers 
than non-smokers. It seems that smoking may interrupt the mechanism regulating leptin 
levels. In order to comprehend the possible underlying mechanisms on  regulation of leptin, 
Nagayasu S et al., conducted a study to examine the effects of smoking and inflammation on 
leptin regulation  at cellular levels by gene expression analyses. They noticed that nicotine 
markedly suppressed the adipocyte expression of leptin gene  in the presence of 
macrophages. Additionally, the observed suppressive effects of nicotin could also be 
mediated by catecholamines but there was no direct  suppressive action on adipocytes.
51
 In 
order to avoid leptin derived from smokers biasing the estimation of leptin concentration, 
smokers were excluded from the study.  
Pregnant women had been excluded from the study because it has been demonstrated 
that they exhibit higher serum leptin levels in pregnant women than in puerperal women 
which may be ascribable to  an excessive production of leptin from maternal adipose tissue 
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that is stimulated by high concentrations of serum estradiol and leptin production from the 
placenta.
52
 
Shi D et al observed that the plasma leptin level is higher in patients with Aggressive 
Periodontitis than chronic periodontitis with comparable Probing Depth. Leptin exhibited  a  
positive association with systemic inflammatory markers including WBC and neutrophil 
counts, IL-1and IL-6 in patients with Aggressive Periodontitis. These results imply that 
leptin shows an interdependence between local infection and systemic health.
53
 Hence, 
patients with Aggressive Periodontitis were exempted from the study.      
In the present study, serum leptin levels are elevated in chronic 
periodontitis(288.263±64.7439 pg/ml) than healthy individuals (26.412±8.6102 pg/ml), in 
the same way as other cytokines. These findings corroborate with the studies done by 
Shimada et al,
19
 Sete et al,
54
 Purwar et al, 
55
 Mendoza et al,
56
 Karthikeyan et al,
57
 Kanoriya 
et al,
58
 Gonclaves et al
59
 and Cosidine et al.
60
On the contrary,Mendoza-Azpur G, observed 
lowest leptin levels  in normal weight subjects with CP instead of  normal weight subjects 
without CP.
56
 
 The etiology for its rise of serum levels in chronic periodontitis was explained by the 
following studies. Kim SJ et al. found that Leptin potentiates the production of TNF-alpha 
induced by Prevotella intermedia lipopolysaccharide in monocyte-derived macrophages. 
This could account for high levels of leptin observed in the serum of patients with 
periodontitis in this study and other investigations.
61
Williams RCet al.studied  whether 
leptin has a solitary or synergistic action with inflammatory mediators in transforming the 
gene expression involved in ECM remodelling of Human Gingival Fibroblasts, with a 
special attention on the collagenase MMP-1, and the stromelysin MMP-3. They  found that 
leptin enhanced the secretion of MMP-1 and MMP-3 in a dose-dependent manner and acts 
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synergistically with IL-1  to up-regulate MMP-1, MMP-3, MMP-8 and MMP-12 expression 
by Human Gingival Fibroblasts, which was regulated by Mitogen Activated Protein Kinase 
and Signal Transducer and Activator of Transcription 3 (MAPK and STAT3) signalling. 
Their  results suggest that degradation of ECM may be deleteriously intensified by 
hyperleptinaemia.
62
 Thus matrix degradation enhanced by hyperleptinaemia could be one of 
the reasons for progression of periodontitis.  
Genco et al. emphasized that the elevated levels of serum leptin stimulate the secretion 
of endotoxins by adipose tissue triggered by lipopolysaccharides, which further promote the 
generation of inflammatory cytokines, leading to additional destruction of periodontium.
63
 
The variety of enzymes, hormones, antibodies, antimicrobial constituents, and growth 
factors are incorporated into the oral cavity from the blood through the transcellular and 
paracellular routes. Hence biologic fluids of the oral cavity, similar to serum,  reflects the 
physiological state of the body, including nutritional, emotional, hormonal and metabolic 
variations. These properties open doors to a perfect method of exploring health and disease 
surveillance in clinical settings with just a minute amount of the oral fluid. 
Plentiful studies have been carried out to estimate the levels of leptin in GCF. Johnson 
and Serio
10
 in 2001 evaluated leptin concentrations in healthy and diseased gingiva with the 
use of ELISA. Higher concentrations of leptin is observed in gingival tissues  adjacent to a 
sulcus depth ≤3mm and reduces progressively in inflamed gingiva with periodontal pockets 
>3mm. These results are similar to the results of the present study, in which the salivary 
leptin levels are elevated in healthy subjects  and reduced in patients with periodontitis. 
They suggested that the expansion of the vascular  network caused by vascular endothelial  
growth factor during inflammatory conditions enhance the rate of removal of leptin levels 
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from the diseased gingiva thereby elevating the serum leptin level. They also proposed that 
high concentrations of gingival leptin play a protective role.  
Karthikeyan and Pradeep
64
evaluated GCF leptin levels in periodontally healthy and 
diseased  subjects  with normal BMI. The GCF leptin levels were statistically higher in 
healthy subjects than in those of patients with chronic gingivitis and periodontitis. They 
speculated that the progressive decline of leptin levels in gingiva during periodontal disease 
may be due to the lack of adipocytes which will increase the leptin concentration when acted 
upon by these cytokines. 
Similar to the above study, Selvarajan et al.,2015
65
observed a  potential protective 
role for leptin with regard to periodontal health. However, there was a substantial reduction  
in leptin levels in GCF as the deterioration of periodontal tissues progressed, which leads to 
deprivation of  protective effects of leptin on the gingival tissues due to impairement of  
leptin receptor expressionas a result of  inflammation in vascular endothelial cells. In 
addition, they also identified that there was no significant difference between GCF levels of 
males and females. On this ground, gender difference of leptin levels were not considered in 
the present study. 
All the aforementioned studies, 
(10,64,65)
 describing about the role of leptin levels in GCF 
are also applicable to saliva owing to the fact that both saliva and GCF  bears a functional 
equality with serum. Saliva which is a complex biological fluid exhibiting preferential 
representation of markers,contains a variety of biomolecules, including DNA, mRNA, 
microRNA, proteins, metabolites and microbiota. The source of leptin in saliva is derived 
locally from salivary glands, gingiva and reaches via passive diffusion or active transport  
from the blood.  The changes in the salivary concentration of these biomolecules can be 
used to develop dysregulated biomarkers  which helps to identify early oral and systemic 
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diseases, evaluate disease prognosis and risk, and monitor the response to treatment. Saliva 
provides an attractive alternative to more invasive, time-consuming, complicated, and 
expensive diagnostic approaches.
66
 
Based on this contemplation, the present study and few other studies by Groschl et al., 
2001,
12
 Thanakun et al.,2014,
67
  Purwar et al.,2015,
55
 Khorsand et al., 2016
68
  have 
evaluated salivary leptin levels in chronic periodontitis. All the above studies have proved 
that salivary leptin levels are significantly lower in chronic periodontitis compared to 
healthy individuals. These results are consistent with the present study in which the salivary 
leptin levels of chronic periodontitis patients (3.153± .2058) were significantly lower than 
healthy individuals (10.450± 3.9180) andshowed a strongly negative correlation to PD and 
CAL potentiating the protective role ofleptin in oral health 
Due to the presence of higher levels of protein concentration in unstimulated whole 
saliva, it  harmonises with systemic clinical conditions more accurately than stimulated 
saliva.
12
 Pertaining to this reason, the present study involved in the collection of 
unstimulated saliva. Salivary leptin levels of periodontally healthy individuals range from 
5.3-17.9 pg/ml which synchronises with the study done by Thanakun 2013
69
 using the same 
ELISA kit (RayBio®, GA, USA). He also found the salivary leptin levels of  healthy 
individuals  to be 5.77- 17.09pg/ml. 
Thomas et al. assessed the effects of human recombinant leptin on a conditionally 
immortalized human marrow stromal cell which serves as a common precursor for both 
osteoblasts and adipocytes. Their data showed that osteoblastic differentiation of marrow 
progenitors was enhanced by leptin whereas late adipocytic differentiation was inhibited by 
leptin. In addition to its action on the central nervous system, their study substantiated the 
role of leptin in bone formation on account of its direct effect on high affinity leptin 
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receptors on cells  in peripheral tissues, thus enhancing the proliferation, differentiation of 
human primary osteoblasts and prolonging its life span  by inhibiting apoptosis.
70
 It is quite 
evident from the above study that higher salivary leptin concentrations in the healthy 
individuals , protected the host from inflammation and infection and maintained bone levels. 
The decrease in salivary leptin concentrations in chronic periodontitis may be due to the 
increased expression of leptin receptors during periodontal inflammation owing to the 
cytopathic changes which provoke intensified binding of leptin to these receptors, thereby 
decreasing the concentration of leptin in saliva.
55
 
The preventive effects of leptin on  bacterial growth have been reported in the 
respiratory mucosa of mice conducted by Hsu et al. They found that leptin prevented 
decrease in the synthesis of mucin in salivary glands even after the activation of 
lipopolysaccharides.
71
  It also appears to have anti-inflammatory effects. Salivary leptin 
exerts significant  physiologic effects on oral keratinocytes. Such an effect has an important 
role in wound healing  in the oral mucosa.
72
 The exact  mechanism of its protective role has 
not been  ascertained yet. It appears that leptin is used as a  substrate during the 
inflammatory process. However, enormous evidence conceptualizes the protective role of 
leptin at higher concentration in saliva. 
As it is obvious that localized infection resulting in chronic inflammation may lead to 
coronary heart disease(CHD), Periodontal disease is a risk factor for CHD, independent of 
other classic risk factors. Though lipopolysaccharide and monocyte-related responses 
provide a link between periodontitis and cardiovascular disease, leptin also has the ability to 
promote proinflammatory signaling through cytokines and growth factors, leading to the 
production  of adhesion molecules such as vascular cell  adhesion molecule 1, E-selectin, 
and intracellular cell  adhesion molecule 1, thereby adherence  of monocytes are enhanced, 
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which may contribute to endothelial dysfunction, atherosclerosis.
73
  There has been a 
hypothesis stating that increased serum leptin concentrations up to 10,000 pg/mL in 
inflammatory conditions could be a risk marker for future cardiovascular disease but it has 
to be confirmed by further studies.    
 Leira estimated serum leptin levels in patients with Chronic Migraine with and without 
chronic periodontitis (CP).  Chronic migraine patients with CP showed significantly higher 
leptin concentrations than Chronic Migraine patients without CP. Furthermore, leptin was 
found to be associated with the presence of migraine, concluding that this biomarker could 
play a role in the pathogenesis of migraine. Therefore, it could be inferred that CP via leptin 
may be involved in the process of migraine chronification.
74
Based on the previous studies, it 
can be emphasized that periodontitis via leptin  has an association with other systemic 
diseases. 
Non Surgical Periodontal Therapy (NSPT) is a critical aspect of periodontal treatment. 
Long term success of the periodontal treatment depends predominantly on maintaining the 
results achieved with phase I therapy and much less on any surgical procedures. Hence this 
study has performed NSPT to focus on alterations of serum and salivary leptin levels. All 
the clinical parameters (PI, GI, GBI, PD, CAL) showed improvement after 3 months of 
NSPT and also showed a significant reduction in serum leptin levels (288.263±64.743 to 
77.330± 7.150 pg/ml)and an increase in salivary leptin levels (3.153± .2058 to 10.897± 
3.665 pg/ml).  
 Correspondingly, in a study done by Purwar et al.,
18
 serum leptin levels which was 
higher in chronic periodontitis patients showed a significant reduction after 12 weeks of 
NSPT and the converse took place in salivary leptin levels. These results are analogous to 
the present study. 
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Shimada et al. evaluated the effectiveness of periodontal treatment on serum leptin, 
interleukin (IL) 6, and C-reactive protein (CRP). Nonsurgical therapy significantly reduced 
the serum leptin, IL-6, and CRP levels after one month in accordance with the periodontal 
clinical parameters
19
 which was congruent to the present study.    
Meharwade et al 
75
 conducted a split mouth study to evaluate the effect of nonsurgical 
periodontal treatment with and without local drug delivery on the gingival crevicular fluid 
(GCF) leptin levels from ninety sites of 30 nonobese chronic periodontitis patients. Clinical 
parameters improved after periodontal therapy in all patients. Patients who were treated with 
SRP+ tetracycline local drug delivery showed more significant reduction in leptin levels 
after 15 days than in patients treated with SRP but GCF leptin reelevated to almost the 
pretreatment level after 45 days. Their study stressed on the fact that indoctrinating the 
patient in a recall pattern and reinforcing the patient to maintain meticulous personal oral 
hygiene is also essential to amend the leptin levels. 
 The present study proves that periodontitis upregulate serum leptin and downregulate 
salivary leptin levels and NSPT along with meticulous maintenance care can restore the 
leptin levels to health. Thus leptin serves as a potential marker to provide insight beyondthe 
classic clinical and radiographicfindings of the disease process. .Moreover, though leptin can 
be a indicative biomarker of periodontal disease progression, it is unlikely that one 
standalone biomarker will present with sufficiently high sensitivity and specificity level to 
meet the criteria of a diagnostic tool. 
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The following major conclusions can be drawn from this study:  
(1) Patients with chronic periodontitis exhibited higher levels of serum leptin compared to 
periodontally healthy individuals 
(2) Salivary leptin levels were lower in the chronic periodontitis patients than healthy 
controls 
(3) Serum leptin levels correlated positively with probing depth and clinical attachment level 
whereas salivary leptin levels correlated negatively. 
(3) Non-surgical periodontal therapy amended salivary and serum leptin levels towards 
health.  
As the salivary leptin levels decline with the progression of periodontitis, 
determination of salivary levels of leptin can be done as a simple and non-invasive 
alternative technique to determine the susceptibility to chronic periodontitis.  
It can be concluded that leptin might play a role as a new biomarker associating 
periodontitis with systemic diseases and NSPT not only halt the progression of periodontitis 
alone but also eliminates the risk of developing systemic diseases.  Though advanced 
modalities of periodontal therapy have been developed, NSPT still remains the cornerstone 
of periodontal treatment and systemic health maintenance. 
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